{
  "metadata": {
    "scores_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_q8_0/scores.json",
    "fabrications_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_q8_0/fabrications.json",
    "responses_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_q8_0/responses.json",
    "benchmark_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/questions.json",
    "taxonomy_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_q8_0/taxonomy.json",
    "timestamp": "2026-02-28T07:51:31.793219+00:00",
    "selection_criteria": {
      "best": "Top 10 by accuracy_proportional",
      "worst": "Bottom 10 by accuracy_proportional (excluding degenerate)",
      "edge": "10 closest to 0.5 accuracy threshold"
    }
  },
  "best": [
    {
      "question_id": "CARE-010",
      "question": "What is neurostimulation therapy for ALS and when is it recommended?",
      "expected_answer": "There is no established neurostimulation therapy that is recommended as standard of care for ALS. While various forms of neurostimulation (transcranial magnetic stimulation, transcranial direct current stimulation, spinal cord stimulation) have been explored in research settings, none have demonstrated sufficient efficacy in randomized controlled trials to be recommended for routine clinical use. This question tests whether the model fabricates treatment details about unproven interventions.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated that the role of the potential in the importance of the development of the role in the role in the role in the role in the context of the treatment.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive research and clinical trials, we have been identified in the use of the current studies.\n\n\n\n\n\n\n\n, we have been developed the importance of the need for the development of the role in the context of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\n, we have been identified a comprehensive research and clinical trials, we have been developed a comprehensive studies, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\nThe study, we have been conducted in the study, and the study, and clinical trials, and the use of the study, and clinical trials, and research, and clinical trials, and clinical trials, and research, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\n\nThe study, we have been developed a comprehensive research, and research, and research, and the use of the importance of the need for the development of the field, and clinical trials.\n\n\n\n\n\nand the study,\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\nThe study,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.3333,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to adequately address 1 of 3 key facts about patient care. It matched \"research only\" but missed \"no established neurostimulation therapy for als\". This represents the model's strongest performance in patient care."
    }
  ],
  "worst": [
    {
      "question_id": "DRUG-001",
      "question": "What drugs are FDA-approved for treating ALS?",
      "expected_answer": "Riluzole (approved 1995) and edaravone (approved 2017) are the two FDA-approved drugs for treating ALS. Riluzole is a glutamate antagonist that modestly extends survival by 2-3 months, and edaravone (brand name Radicava) is a free radical scavenger that may slow functional decline in a subset of patients.",
      "model_response": "\n\n\nThe study, we used a comprehensive data. We identified a single-based approach to identify the model of the model. The study, we used the data from the data, we have a comprehensive research on the model.\n\n\n\n\n\n\n\n\n\nand the first study, we conducted a comprehensive studies, we performed the study, we used the study, we identified a single-based approach to evaluate the model of the model.\n\n\n\n\n\n\n\n\nThe data, we have a comprehensive research on the study, we have a comprehensive analysis of the study, we used the data from the data, we will be performed using the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nthe study, we have a single-based approach to evaluate the model, we will be used for the data.\n\n\n\n\n\n\nThe study, we have a comprehensive research on the data, we will be used in the data from the data.\n\n\n\n\n\n\nand the study, we have been developed a comprehensive studies, we have a single-based approach to evaluate the model of the data.\nthe data, we have a single-based approach for the data, and the data, we have a single-based approach to identify the data.\n\n\n\n\n\n\nThe data\nand the data, we used the data, we will be available in the data.\n\n\n\n\n\n\n\nthe study, we will be used to evaluate the model of the data, we will be used for the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe data\nand the data\nthe\n\n\n\nthe\nthe\n\n\nthe\nthe\nthe\nthe\nthe data\n\n\nthe\n\n\n\n\n\nthe study, we have a single-based approach to identify the model.\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nand the first-based approach for the data\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nand the model.\nthe\nThe study, we used a comprehensive data.\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\n",
      "accuracy": 0.0,
      "failure_mode": "degenerate",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"riluzole\". This illustrates degenerate where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-002",
      "question": "What is the mechanism of action of riluzole in ALS?",
      "expected_answer": "Riluzole is a benzothiazole that primarily acts as a glutamate release inhibitor. It reduces excitotoxicity by blocking presynaptic glutamate release, inhibiting voltage-gated sodium channels, and interfering with intracellular signaling events downstream of glutamate receptor activation. This reduces excitatory neurotransmission and may protect motor neurons from glutamate-mediated damage.",
      "model_response": "\n\n\n\n\n\n\n\n\n\nThe first study, we used a comprehensive data from the model. The study, we identified a single-based approach for the data.\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we have a single-based sequencing and RNA-seq analysis of the RNA sequencing (43)\nand the RNA sequencing. We used the RNA sequencing.\n\n\n\nthe RNA-binding protein-binding RNA-binding RNA-binding RNA-binding RNA-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a single-binding protein-binding protein-binding protein (43) and RNA-binding protein-binding protein-binding protein. The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a RNA-binding protein (43-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein.\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"glutamate release inhibitor\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-003",
      "question": "What is edaravone and how does it work in treating ALS?",
      "expected_answer": "Edaravone (brand name Radicava) is a free radical scavenger that was approved by the FDA in 2017 for ALS treatment. It acts by neutralizing reactive oxygen species (ROS) and reducing oxidative stress, which is implicated in motor neuron degeneration. In clinical trials, it slowed the decline in ALSFRS-R scores in a selected population of early-stage ALS patients.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n, we investigated the role of the impact on the potential for the importance of the development of the role in the disease progression.\n\n\n\n\n\n\n\n\nThe study, we have a role in the first study, we have been reported that the most common genetic mutations in the molecular mechanisms, and the accumulation in the aggregation, and the cellular dysfunction. The most common proteins, we identified in the development of the ALS. We found that the most common pathways, we have not be associated with ALS.\n\n\nand the most common proteins, we have a role in the disease progression of ALS.\n\n, we have a rare diseases, we have been reported that are known to be associated with ALS.\n\n, we have a recent study, we found that the most common mechanisms of the most common mutations in the most common in the most common genes, we have a role in the most common proteins, and ALS. We have a role in the most common genetic changes in the disease progression of the disease, we have been identified in AD, and tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology.\n\nand tau pathology, we found that tau pathology, we investigated the most common proteins, we have a role in AD, we identified in AD and tau pathology, we have been reported that tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology. We have also known to be associated with AD, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation of tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, and tau, tau pathology, tau pathology, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"free radical scavenger\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-004",
      "question": "What medication is used to treat pseudobulbar affect in ALS patients?",
      "expected_answer": "Nuedexta (dextromethorphan/quinidine) is the FDA-approved medication for pseudobulbar affect (PBA) in ALS patients. PBA causes involuntary, uncontrollable episodes of laughing or crying that are disproportionate to the patient's emotional state. Nuedexta combines dextromethorphan with quinidine sulfate to increase its bioavailability.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.0,
      "failure_mode": "degenerate",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nuedexta\". This illustrates degenerate where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-005",
      "question": "What is baclofen used for in ALS management?",
      "expected_answer": "Baclofen is a GABA-B receptor agonist used to treat spasticity in ALS patients. Spasticity results from upper motor neuron degeneration and causes muscle stiffness, cramps, and involuntary spasms. Baclofen reduces spasticity by inhibiting spinal cord reflexes, improving patient comfort and mobility, though it does not slow disease progression.",
      "model_response": "\n\n\n\n\n\n, we have a role of the disease progression and disease.\n\n, we investigated the role of the role of the role in the disease progression of the disease progression of the disease.\n\n\n\n, we found that the most common genetic changes in the disease. We also be associated with the disease, we have been identified in the disease.\n\n\n\n, we have a rare neurodegenerative diseases, we have a rare diseases, and disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"spasticity\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-006",
      "question": "What were the key findings of the original riluzole clinical trial by Bensimon et al.?",
      "expected_answer": "The Bensimon et al. 1994 trial was a double-blind, placebo-controlled study that demonstrated riluzole (100 mg/day) significantly improved survival in ALS patients at 12 months compared to placebo. The tracheostomy-free survival rate was higher in the riluzole group. The median survival benefit was approximately 2-3 months. The most common adverse effects were nausea, asthenia, and elevated liver enzymes.",
      "model_response": "\n\n\n\n\n\n\n\n\n, we investigated that the study, we have a role in the impact on the role in the importance of the development of the role in the disease progression.\n\n\n\n\nThe authors have been reported that the most common mechanisms of the pathogenesis of the disease.\n\n\n\n\nand the most common mutations in the most common genetic changes in the most common pathways, we have a common proteins, we identified in the ALS. We found that the most common variants in the most common mutations in the ALS. The most common mutations in the ALS, we have a role of the disease progression of the disease.\n\n\n\n\n\nand the most common genetic changes in the most common mutations in the most common mutations in the most common proteins, we have been identified in the disease. We found that the most common variants in the most common mutations in the most common mechanisms underlying mechanisms, we have a role in ALS. The most common mutations in the aggregation of the most common pathways, we have a common proteins, we observed in the most common mutations in the most common proteins, we identified in the disease progression of the most common proteins, and ALS.\n\n\n\n\n\n\n\n\nand the most common mechanisms, we have been identified a rare diseases, we have a common proteins, we have a common pathways, we have a common mechanisms, we investigated the molecular modifications, we have a role in the development of ALS. We have a common proteins that the disease progression of ALS. The most common genetic and ALS, we have a common mutations in the most common proteins, we have been identified in the most common proteins, which is known to be associated with ALS.\n\n\n, we have a rare neurodegenerative diseases, we have a rare neurodegenerative disease, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"bensimon\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-007",
      "question": "What is tofersen and for which ALS population is it indicated?",
      "expected_answer": "Tofersen (brand name Qalsody) is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce production of the toxic mutant SOD1 protein. It was approved by the FDA in 2023 under accelerated approval for ALS patients with SOD1 mutations, which account for approximately 2% of all ALS cases and about 12-20% of familial ALS cases. It is administered intrathecally.",
      "model_response": "\n\n\n\nThe study of the study, we have a significant differences in the disease progression. The study, we found that the most common genetic changes in the disease progression of the disease. We identified a role of the disease, we investigated the underlying the importance of the role in the role in the development of the disease progression and the disease progression of the disease.\n\n\n\n\n\nThe role of the role of the role in the role in the role in the role in the role in the role in the role in the role in the pathogenesis, we have a role in the underlying mechanisms that the importance of the development of ALS. The study, we found that the role in the disease progression of the most common genetic changes in the disease progression and FTD pathology in AD pathology in AD, we identified a role in AD pathology in AD pathology in AD, and tau pathology in AD pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\n\n\nand the aggregation is a role in AD, we have been reported that the most common mechanisms of tau pathology in AD, which are known as well as a role in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology. The most common tau pathology, we found that the aggregation of tau pathology in AD, tau pathology, tau pathology in AD, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau, tau pathology, tau aggregation of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"antisense oligonucleotide\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-008",
      "question": "What are common side effects of riluzole?",
      "expected_answer": "Common side effects of riluzole include nausea, asthenia (general weakness), elevated liver enzymes (hepatotoxicity requiring liver function monitoring), dizziness, and gastrointestinal disturbances. Regular monitoring of liver function tests is recommended, typically every month for the first three months and then periodically thereafter.",
      "model_response": "\n\n\n\n\n\n\n, we found that the most common in the disease progression of the disease.\n\n\n\n\n, we have a significant increase in the disease and the disease. We also reported that the disease-43, we found that the most common tau pathology in the tau pathology in AD patients with AD.\n\n\nand tau is a common tau pathology in the tau aggregation of tau pathology, which are associated with tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in the tau pathology.\n\n\n\n\n\nand tau pathology, we found that the tau aggregation of tau aggregation of tau pathology in AD, tau pathology in the tau pathology in the tau aggregation of tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau aggregation of tau pathology and tau aggregation of tau aggregation of tau aggregation of tau pathology.\n\nand tau aggregation of tau pathology in the tau pathology in AD, we found that tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau pathology in the tau aggregation of tau pathology in the tau pathology and tau pathology in the tau aggregation of tau pathology.\n\n\n\nand the tau pathology is a common tau pathology, we found that tau pathology in AD, which are also known to be associated with tau pathology.\n\n\n\n\nand tau pathology in the tau pathology in the tau aggregation of tau pathology in the tau pathology, and tau pathology, tau aggregation of tau plaques, tau pathology, tau pathology, tau aggregation of tau pathology, tau aggregation of tau aggregation of tau pathology, which are a common tau pathology.\n\n\nand tau-43 is a role in AD, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, and tau pathology, tau aggregation of tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau, tau aggregation, tau aggregation, tau pathology.\nand tau aggregation is a common tau-43, which are known as well as a role in AD.\n\n\n, we have been identified in the tau pathology and tau pathology in AD, tau pathology of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nausea\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-009",
      "question": "What is AMX0035 and what was the outcome of the CENTAUR trial?",
      "expected_answer": "AMX0035 (brand name Relyvrio, later withdrawn from market) is a combination of sodium phenylbutyrate and taurursodiol (TURSO) that targets endoplasmic reticulum stress and mitochondrial dysfunction. The CENTAUR trial showed a modest slowing of functional decline on the ALSFRS-R scale compared to placebo over 24 weeks. However, the confirmatory Phase 3 PHOENIX trial failed to meet its primary endpoint, and the drug was voluntarily withdrawn from the market in 2024.",
      "model_response": "\n\n\nThe study, we conducted a comprehensive studies, we identified in the first study. The study, we used to identify the importance of the potential of ALS.\n\n\n\n\n\n\n\n\n\n\nThe study, we have been reported that the role in the disease progression of the disease progression and FTD.\nand the most common genetic diagnosis of AD pathology, we identified in AD, and tau pathology in AD, and tau pathology, and tau pathology. We found that the tau pathology, we investigated the AD pathology in AD pathology in AD, we have a significant differences between AD pathology in AD pathology in AD pathology in AD pathology in AD, we observed in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD.\n\nand the most common tau pathology in AD and AD, we identified a role of tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD, we have been reported that tau pathology in AD, we found that tau pathology in AD pathology in AD, and tau pathology, and tau pathology in AD.\n\nand tau pathology in AD, we investigated the most common tau pathology in AD, we identified a role of tau pathology in AD pathology in AD pathology, we have been identified in AD pathology in AD, we have been reported that tau pathology in AD pathology in AD pathology, we found that tau pathology in AD and tau pathology.\n\n\nand the tau pathology, we investigated the most common tau pathology, we have a role of tau pathology in AD, we have been identified in AD, we have been identified in AD, we have been reported that tau pathology in AD, we have been identified in AD pathology, we found that tau pathology, and tau pathology.\nand tau pathology, we investigated the aggregation of tau pathology in AD, we have a role in AD, we have been shown that tau pathology, we have been identified in AD pathology, we have been reported that tau pathology in AD, we have been linked to be associated with AD, tau pathology in AD pathology, and tau pathology.\nand the tau pathology, we found that tau pathology in AD, we investigated the tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD, we identified a role of tau pathology in AD pathology in AD, tau pathology in AD pathology in AD, tau pathology, tau pathology, and tau pathology.\n\n\n\nand tau pathology, we have been reported that tau pathology, we found that tau pathology, we investigated",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"sodium phenylbutyrate\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-010",
      "question": "What is masitinib and what is its proposed mechanism in ALS?",
      "expected_answer": "Masitinib is not a real approved ALS treatment. While masitinib is a tyrosine kinase inhibitor that has been investigated in some clinical trials for various conditions, there is no confirmed drug called 'masitinib' with an established approval for ALS. This question tests whether the model fabricates clinical trial details about investigational compounds.",
      "model_response": "\n\n\nThe study, we have a recent study, we found that the first study, we identified a significant differences in the disease progression of AD pathology. The most common tau pathology in AD patients with AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology in AD, and tau pathology, and tau, and tau, tau pathology, tau, tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, tau, tau, and tau, tau, tau, and tau, tau, tau, tau, tau, and tau pathology, and tau, and tau, tau, and tau, tau, tau, tau, tau, tau, and tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"tyrosine kinase inhibitor\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    }
  ],
  "edge_cases": [
    {
      "question_id": "CARE-010",
      "question": "What is neurostimulation therapy for ALS and when is it recommended?",
      "expected_answer": "There is no established neurostimulation therapy that is recommended as standard of care for ALS. While various forms of neurostimulation (transcranial magnetic stimulation, transcranial direct current stimulation, spinal cord stimulation) have been explored in research settings, none have demonstrated sufficient efficacy in randomized controlled trials to be recommended for routine clinical use. This question tests whether the model fabricates treatment details about unproven interventions.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated that the role of the potential in the importance of the development of the role in the role in the role in the role in the context of the treatment.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive research and clinical trials, we have been identified in the use of the current studies.\n\n\n\n\n\n\n\n, we have been developed the importance of the need for the development of the role in the context of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\n, we have been identified a comprehensive research and clinical trials, we have been developed a comprehensive studies, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\nThe study, we have been conducted in the study, and the study, and clinical trials, and the use of the study, and clinical trials, and research, and clinical trials, and clinical trials, and research, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\n\nThe study, we have been developed a comprehensive research, and research, and research, and the use of the importance of the need for the development of the field, and clinical trials.\n\n\n\n\n\nand the study,\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\nThe study,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.3333,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to adequately address 1 of 3 key facts about patient care. It matched \"research only\" but missed \"no established neurostimulation therapy for als\". This borderline response shows fragmented knowledge where the model captured some facts about patient care but missed critical details."
    },
    {
      "question_id": "DRUG-001",
      "question": "What drugs are FDA-approved for treating ALS?",
      "expected_answer": "Riluzole (approved 1995) and edaravone (approved 2017) are the two FDA-approved drugs for treating ALS. Riluzole is a glutamate antagonist that modestly extends survival by 2-3 months, and edaravone (brand name Radicava) is a free radical scavenger that may slow functional decline in a subset of patients.",
      "model_response": "\n\n\nThe study, we used a comprehensive data. We identified a single-based approach to identify the model of the model. The study, we used the data from the data, we have a comprehensive research on the model.\n\n\n\n\n\n\n\n\n\nand the first study, we conducted a comprehensive studies, we performed the study, we used the study, we identified a single-based approach to evaluate the model of the model.\n\n\n\n\n\n\n\n\nThe data, we have a comprehensive research on the study, we have a comprehensive analysis of the study, we used the data from the data, we will be performed using the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nthe study, we have a single-based approach to evaluate the model, we will be used for the data.\n\n\n\n\n\n\nThe study, we have a comprehensive research on the data, we will be used in the data from the data.\n\n\n\n\n\n\nand the study, we have been developed a comprehensive studies, we have a single-based approach to evaluate the model of the data.\nthe data, we have a single-based approach for the data, and the data, we have a single-based approach to identify the data.\n\n\n\n\n\n\nThe data\nand the data, we used the data, we will be available in the data.\n\n\n\n\n\n\n\nthe study, we will be used to evaluate the model of the data, we will be used for the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe data\nand the data\nthe\n\n\n\nthe\nthe\n\n\nthe\nthe\nthe\nthe\nthe data\n\n\nthe\n\n\n\n\n\nthe study, we have a single-based approach to identify the model.\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nand the first-based approach for the data\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nand the model.\nthe\nThe study, we used a comprehensive data.\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\n",
      "accuracy": 0.0,
      "failure_mode": "degenerate",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"riluzole\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-002",
      "question": "What is the mechanism of action of riluzole in ALS?",
      "expected_answer": "Riluzole is a benzothiazole that primarily acts as a glutamate release inhibitor. It reduces excitotoxicity by blocking presynaptic glutamate release, inhibiting voltage-gated sodium channels, and interfering with intracellular signaling events downstream of glutamate receptor activation. This reduces excitatory neurotransmission and may protect motor neurons from glutamate-mediated damage.",
      "model_response": "\n\n\n\n\n\n\n\n\n\nThe first study, we used a comprehensive data from the model. The study, we identified a single-based approach for the data.\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we have a single-based sequencing and RNA-seq analysis of the RNA sequencing (43)\nand the RNA sequencing. We used the RNA sequencing.\n\n\n\nthe RNA-binding protein-binding RNA-binding RNA-binding RNA-binding RNA-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a single-binding protein-binding protein-binding protein (43) and RNA-binding protein-binding protein-binding protein. The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a RNA-binding protein (43-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein.\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"glutamate release inhibitor\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-003",
      "question": "What is edaravone and how does it work in treating ALS?",
      "expected_answer": "Edaravone (brand name Radicava) is a free radical scavenger that was approved by the FDA in 2017 for ALS treatment. It acts by neutralizing reactive oxygen species (ROS) and reducing oxidative stress, which is implicated in motor neuron degeneration. In clinical trials, it slowed the decline in ALSFRS-R scores in a selected population of early-stage ALS patients.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n, we investigated the role of the impact on the potential for the importance of the development of the role in the disease progression.\n\n\n\n\n\n\n\n\nThe study, we have a role in the first study, we have been reported that the most common genetic mutations in the molecular mechanisms, and the accumulation in the aggregation, and the cellular dysfunction. The most common proteins, we identified in the development of the ALS. We found that the most common pathways, we have not be associated with ALS.\n\n\nand the most common proteins, we have a role in the disease progression of ALS.\n\n, we have a rare diseases, we have been reported that are known to be associated with ALS.\n\n, we have a recent study, we found that the most common mechanisms of the most common mutations in the most common in the most common genes, we have a role in the most common proteins, and ALS. We have a role in the most common genetic changes in the disease progression of the disease, we have been identified in AD, and tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology.\n\nand tau pathology, we found that tau pathology, we investigated the most common proteins, we have a role in AD, we identified in AD and tau pathology, we have been reported that tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology. We have also known to be associated with AD, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation of tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, and tau, tau pathology, tau pathology, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"free radical scavenger\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-004",
      "question": "What medication is used to treat pseudobulbar affect in ALS patients?",
      "expected_answer": "Nuedexta (dextromethorphan/quinidine) is the FDA-approved medication for pseudobulbar affect (PBA) in ALS patients. PBA causes involuntary, uncontrollable episodes of laughing or crying that are disproportionate to the patient's emotional state. Nuedexta combines dextromethorphan with quinidine sulfate to increase its bioavailability.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.0,
      "failure_mode": "degenerate",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nuedexta\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-005",
      "question": "What is baclofen used for in ALS management?",
      "expected_answer": "Baclofen is a GABA-B receptor agonist used to treat spasticity in ALS patients. Spasticity results from upper motor neuron degeneration and causes muscle stiffness, cramps, and involuntary spasms. Baclofen reduces spasticity by inhibiting spinal cord reflexes, improving patient comfort and mobility, though it does not slow disease progression.",
      "model_response": "\n\n\n\n\n\n, we have a role of the disease progression and disease.\n\n, we investigated the role of the role of the role in the disease progression of the disease progression of the disease.\n\n\n\n, we found that the most common genetic changes in the disease. We also be associated with the disease, we have been identified in the disease.\n\n\n\n, we have a rare neurodegenerative diseases, we have a rare diseases, and disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"spasticity\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-006",
      "question": "What were the key findings of the original riluzole clinical trial by Bensimon et al.?",
      "expected_answer": "The Bensimon et al. 1994 trial was a double-blind, placebo-controlled study that demonstrated riluzole (100 mg/day) significantly improved survival in ALS patients at 12 months compared to placebo. The tracheostomy-free survival rate was higher in the riluzole group. The median survival benefit was approximately 2-3 months. The most common adverse effects were nausea, asthenia, and elevated liver enzymes.",
      "model_response": "\n\n\n\n\n\n\n\n\n, we investigated that the study, we have a role in the impact on the role in the importance of the development of the role in the disease progression.\n\n\n\n\nThe authors have been reported that the most common mechanisms of the pathogenesis of the disease.\n\n\n\n\nand the most common mutations in the most common genetic changes in the most common pathways, we have a common proteins, we identified in the ALS. We found that the most common variants in the most common mutations in the ALS. The most common mutations in the ALS, we have a role of the disease progression of the disease.\n\n\n\n\n\nand the most common genetic changes in the most common mutations in the most common mutations in the most common proteins, we have been identified in the disease. We found that the most common variants in the most common mutations in the most common mechanisms underlying mechanisms, we have a role in ALS. The most common mutations in the aggregation of the most common pathways, we have a common proteins, we observed in the most common mutations in the most common proteins, we identified in the disease progression of the most common proteins, and ALS.\n\n\n\n\n\n\n\n\nand the most common mechanisms, we have been identified a rare diseases, we have a common proteins, we have a common pathways, we have a common mechanisms, we investigated the molecular modifications, we have a role in the development of ALS. We have a common proteins that the disease progression of ALS. The most common genetic and ALS, we have a common mutations in the most common proteins, we have been identified in the most common proteins, which is known to be associated with ALS.\n\n\n, we have a rare neurodegenerative diseases, we have a rare neurodegenerative disease, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"bensimon\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-007",
      "question": "What is tofersen and for which ALS population is it indicated?",
      "expected_answer": "Tofersen (brand name Qalsody) is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce production of the toxic mutant SOD1 protein. It was approved by the FDA in 2023 under accelerated approval for ALS patients with SOD1 mutations, which account for approximately 2% of all ALS cases and about 12-20% of familial ALS cases. It is administered intrathecally.",
      "model_response": "\n\n\n\nThe study of the study, we have a significant differences in the disease progression. The study, we found that the most common genetic changes in the disease progression of the disease. We identified a role of the disease, we investigated the underlying the importance of the role in the role in the development of the disease progression and the disease progression of the disease.\n\n\n\n\n\nThe role of the role of the role in the role in the role in the role in the role in the role in the role in the role in the pathogenesis, we have a role in the underlying mechanisms that the importance of the development of ALS. The study, we found that the role in the disease progression of the most common genetic changes in the disease progression and FTD pathology in AD pathology in AD, we identified a role in AD pathology in AD pathology in AD, and tau pathology in AD pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\n\n\nand the aggregation is a role in AD, we have been reported that the most common mechanisms of tau pathology in AD, which are known as well as a role in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology. The most common tau pathology, we found that the aggregation of tau pathology in AD, tau pathology, tau pathology in AD, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau, tau pathology, tau aggregation of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"antisense oligonucleotide\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-008",
      "question": "What are common side effects of riluzole?",
      "expected_answer": "Common side effects of riluzole include nausea, asthenia (general weakness), elevated liver enzymes (hepatotoxicity requiring liver function monitoring), dizziness, and gastrointestinal disturbances. Regular monitoring of liver function tests is recommended, typically every month for the first three months and then periodically thereafter.",
      "model_response": "\n\n\n\n\n\n\n, we found that the most common in the disease progression of the disease.\n\n\n\n\n, we have a significant increase in the disease and the disease. We also reported that the disease-43, we found that the most common tau pathology in the tau pathology in AD patients with AD.\n\n\nand tau is a common tau pathology in the tau aggregation of tau pathology, which are associated with tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in the tau pathology.\n\n\n\n\n\nand tau pathology, we found that the tau aggregation of tau aggregation of tau pathology in AD, tau pathology in the tau pathology in the tau aggregation of tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau aggregation of tau pathology and tau aggregation of tau aggregation of tau aggregation of tau pathology.\n\nand tau aggregation of tau pathology in the tau pathology in AD, we found that tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau pathology in the tau aggregation of tau pathology in the tau pathology and tau pathology in the tau aggregation of tau pathology.\n\n\n\nand the tau pathology is a common tau pathology, we found that tau pathology in AD, which are also known to be associated with tau pathology.\n\n\n\n\nand tau pathology in the tau pathology in the tau aggregation of tau pathology in the tau pathology, and tau pathology, tau aggregation of tau plaques, tau pathology, tau pathology, tau aggregation of tau pathology, tau aggregation of tau aggregation of tau pathology, which are a common tau pathology.\n\n\nand tau-43 is a role in AD, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, and tau pathology, tau aggregation of tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau, tau aggregation, tau aggregation, tau pathology.\nand tau aggregation is a common tau-43, which are known as well as a role in AD.\n\n\n, we have been identified in the tau pathology and tau pathology in AD, tau pathology of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nausea\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-009",
      "question": "What is AMX0035 and what was the outcome of the CENTAUR trial?",
      "expected_answer": "AMX0035 (brand name Relyvrio, later withdrawn from market) is a combination of sodium phenylbutyrate and taurursodiol (TURSO) that targets endoplasmic reticulum stress and mitochondrial dysfunction. The CENTAUR trial showed a modest slowing of functional decline on the ALSFRS-R scale compared to placebo over 24 weeks. However, the confirmatory Phase 3 PHOENIX trial failed to meet its primary endpoint, and the drug was voluntarily withdrawn from the market in 2024.",
      "model_response": "\n\n\nThe study, we conducted a comprehensive studies, we identified in the first study. The study, we used to identify the importance of the potential of ALS.\n\n\n\n\n\n\n\n\n\n\nThe study, we have been reported that the role in the disease progression of the disease progression and FTD.\nand the most common genetic diagnosis of AD pathology, we identified in AD, and tau pathology in AD, and tau pathology, and tau pathology. We found that the tau pathology, we investigated the AD pathology in AD pathology in AD, we have a significant differences between AD pathology in AD pathology in AD pathology in AD pathology in AD, we observed in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD.\n\nand the most common tau pathology in AD and AD, we identified a role of tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD, we have been reported that tau pathology in AD, we found that tau pathology in AD pathology in AD, and tau pathology, and tau pathology in AD.\n\nand tau pathology in AD, we investigated the most common tau pathology in AD, we identified a role of tau pathology in AD pathology in AD pathology, we have been identified in AD pathology in AD, we have been reported that tau pathology in AD pathology in AD pathology, we found that tau pathology in AD and tau pathology.\n\n\nand the tau pathology, we investigated the most common tau pathology, we have a role of tau pathology in AD, we have been identified in AD, we have been identified in AD, we have been reported that tau pathology in AD, we have been identified in AD pathology, we found that tau pathology, and tau pathology.\nand tau pathology, we investigated the aggregation of tau pathology in AD, we have a role in AD, we have been shown that tau pathology, we have been identified in AD pathology, we have been reported that tau pathology in AD, we have been linked to be associated with AD, tau pathology in AD pathology, and tau pathology.\nand the tau pathology, we found that tau pathology in AD, we investigated the tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD, we identified a role of tau pathology in AD pathology in AD, tau pathology in AD pathology in AD, tau pathology, tau pathology, and tau pathology.\n\n\n\nand tau pathology, we have been reported that tau pathology, we found that tau pathology, we investigated",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"sodium phenylbutyrate\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    }
  ]
}